MATERIAL SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Animal Health
Pfizer Inc
235 East 42nd Street
New York, NY 10017
Poison Control Center Phone: 1-866-531-8896
Technical Services Phone: 1-800-366-5288

Pfizer Ltd,
Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300

Emergency telephone number:
ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Pyrantel Pamoate Paste

Trade Name: STRONGID® Paste ; STRONGID® P
Chemical Family: Mixture
Intended Use: Veterinary product used as anti-worm agent (anthelmintic)

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
Pyrantel pamoate	22204-24-6	244-837-1	43.9
Bronopol	52-51-7	200-143-0	*

Ingredient	CAS Number	EU EINECS List	%
Polysorbate 80	9005-65-6	Not listed	*
Sorbitol solution	50-70-4	200-061-5	*
Sodium alginate	9005-38-3	Not listed	*
Flavor	NOT ASSIGNED	Not listed	*
Purified water	7732-18-5	231-791-2	*
Methylparaben	99-76-3	202-785-7	*
Propylparaben	94-13-3	202-307-7	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: pale yellow to buff paste
Signal Word: WARNING

Statement of Hazard: May cause gastrointestinal, liver, and central nervous system effects
Additional Hazard Information:
Short Term: May cause skin irritation. (based on components) The active ingredient is not acutely toxic.
Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including nausea, vomiting, abdominal cramps, anorexia, diarrhea, and constipation. Central nervous system effects such as dizziness, headache, insomnia, irritability and weakness have also been reported.
EU Indication of danger: Not classified

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Wash skin with soap and water. Remove contaminated clothing and shoes. This material may not be completely removed by conventional laundering. Consult professional laundry service. Do not home launder. If irritation occurs or persists, get medical attention.

Ingestion: Get medical attention immediately. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other sulfur-containing compounds.

Fire Fighting Procedures: Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Evacuate area and fight fire from a safe distance.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Use only in a well-ventilated area. Avoid contact with eyes, skin and clothing. Wash thoroughly after handling.

Storage Conditions: Store in a cool, dry, well-ventilated area. Keep container tightly closed when not in use. Protect from light. Keep out of reach of children.

Storage Temperature: <25°C (<77 °F)

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Pyrantel pamoate

Pfizer OEL TWA-8 Hr: 0.3 mg/m³

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

Analytical Method: Analytical method available for pyrantel pamoate. Contact Pfizer Inc for further information.

Engineering Controls: Engineering controls should be used as the primary means to control exposures. Good general ventilation should be sufficient to control airborne levels. Local and general ventilation should be used as necessary, when handling this material in bulk.

Personal Protective Equipment:

Hands: Rubber gloves
Eyes: Wear safety glasses or goggles if eye contact is possible.
Skin: Wear protective clothing when working with large quantities.
Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Paste
Color: Yellow to buff
Molecular Formula: Mixture
Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Stability: Stable
Conditions to Avoid: None known
Incompatible Materials: Strong oxidizers

Hazardous Decomposition Products: No data available
Polymerization: Will not occur

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the active ingredient.

Acute Toxicity: (Species, Route, End Point, Dose)

Bronopol
Rat (M/F) Oral LD50 307/342 mg/kg
Rat Dermal LD50 1600 mg/kg

Methylparaben
Mouse Oral LD50 > 8000 mg/kg
Rat Oral LD50 2280 mg/kg

Polysorbate 80
Rat Oral LD50 25 g/kg

Propylparaben
Mouse Oral LD 50 6332 mg/kg
Mouse Intraperitoneal LD 50 200 mg/kg

Sorbitol solution
Rat Oral LD50 15,900 mg/kg
Mouse Oral LD50 17,800 mg/kg

Pyrantel pamoate
Mouse Oral LD50 > 24 g/kg
Rat Oral LD50 > 24 g/kg
Mouse Intraperitoneal LD50 620 mg/kg
Rat Intraperitoneal LD50 535 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.
Inhalation Acute Toxicity No data available
Ingestion Acute Toxicity See Acute toxicity table.

Irritation / Sensitization: (Study Type, Species, Severity)

Bronopol
Skin Irritation Rabbit Irritant
Eye Irritation Rabbit Irritant

Eye Irritation / Sensitization No data available
Skin Irritation / Sensitization No data available

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Propylparaben
3 Week(s) Rat Oral 27.1 g/kg LOAEL Endocrine system
4 Week(s) Rat Oral 347.2 mg/kg LOAEL Male reproductive system

Pyrantel pamoate
1 Month(s) Rat Oral 500 mg/kg/day NOAEL None identified
1 Month(s) Dog Oral 50 mg/kg/day LOAEL Gastrointestinal system, Liver
13 Week(s) Rat Oral 300 mg/kg/day NOAEL None identified
13 Week(s) Dog Oral 100 mg/kg/day NOAEL Gastrointestinal system, Liver

Subchronic Effects In dogs, oral administration of pyrantel pamoate produced occasional diarrhea in all treated animals; emesis, tremors, and liver changes were reported at 250 and 500 mg/kg/day for 1 month. In a 13-week oral toxicity study, dogs showed loose stools or diarrhea and increased liver enzymes at doses of 300 and 600 mg/kg/day.

Chronic Toxicity Chronic oral toxicity of pyrantel was conducted in rats and dogs for 2 years using the better absorbed tartrate salt. In rats, depressed weight gain and food consumptiom, depressed red blood cell parameters, and liver changes were observed at 50 and 200 mg/kg/day. In dogs, signs of toxicity included vomiting, salivation, and relaxation of nictitating membranes were observed at 25 mg/kg/day and higher. A dose-related increase in liver weight was also observed at 25 and 50 mg/kg/day.

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Pyrantel pamoate
Reproductive & Fertility Rat Oral 250 mg/kg NOAEL No effects at maximum dose
Prenatal & Postnatal Development Rat Oral 250 mg/kg NOAEL No effects at maximum dose
Embryo / Fetal Development Rat Oral 250 mg/kg NOAEL Not Teratogenic
Embryo / Fetal Development Rabbit Oral 250 mg/kg NOAEL Not Teratogenic

Reproductive Effects No evidence of adverse effects on fertility, reproduction or lactation was observed for pyrantel pamoate in rats at oral doses of 25 or 250 mg/kg/day. No maternal toxicity, embryo or fetotoxicity were observed in perinatal and postnatal toxicity study.

Teratogenicity No evidence of teratogenicity or embryotoxicity was observed for pyrantel pamoate in rats and rabbits at oral doses up to 250 mg/kg/day.

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Pyrantel pamoate
Bacterial Mutagenicity (Ames) *Salmonella* Negative
Mutagenicity Not mutagenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

At increase risk from exposure: Individuals with liver conditions may be more susceptible to the toxicity in cases of overexposure.

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:
WARNING
May cause gastrointestinal, liver, and central nervous system effects

Canada - WHMIS: Classifications

WHMIS hazard class:
None required
This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Pyrantel pamoate

Australia (AICS):	Present
EU EINECS List	244-837-1

Polysorbate 80

Inventory - United States TSCA - Sect. 8(b)	XU
Australia (AICS):	Present

Sorbitol solution

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	200-061-5

Sodium alginate

Inventory - United States TSCA - Sect. 8(b)	XU
Australia (AICS):	Present

Purified water

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	231-791-2

Methylparaben

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	202-785-7

Propylparaben

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	202-307-7

Bronopol

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	200-143-0

16. OTHER INFORMATION

Reasons for Revision: Updated Section 3 - Hazard Identification. Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

End of Safety Data Sheet